Azar Alex M II
Known title: DirectorCIK: 0001402256
Associated companies
Transaction History
| GH | ▼ Sell | Open Market | 826 | $145K | 9/16/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 1,651 | $0 | 9/12/2026 | View on chart |
| GH | ▼ Sell | Open Market | 826 | $145K | 9/16/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 1,651 | $0 | 9/12/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target
Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.
Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target. Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.